(Q30438454)

English

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus (English)

1 reference

Europe PubMed Central

19 August 2017

phase III clinical trial

0 references

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Aaron H Wolfson

1

1 reference

Europe PubMed Central

19 August 2017

Mark F Brady

2

1 reference

Europe PubMed Central

19 August 2017

Thomas Rocereto

3

1 reference

Europe PubMed Central

19 August 2017

Robert S Mannel

4

1 reference

Europe PubMed Central

19 August 2017

Yi-Chun Lee

5

1 reference

Europe PubMed Central

19 August 2017

Robert J Futoran

6

1 reference

Europe PubMed Central

19 August 2017

David E Cohn

7

1 reference

Europe PubMed Central

19 August 2017

Olga B Ioffe

8

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

5 September 2007

1 reference

Europe PubMed Central

19 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

19 August 2017

107

1 reference

Europe PubMed Central

19 August 2017

2

1 reference

Europe PubMed Central

19 August 2017

177-185

1 reference

Europe PubMed Central

19 August 2017

Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Adjuvant chemotherapy in early stage uterine sarcomas: an open question

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

The impact of adjuvant radiotherapy on carcinosarcoma of the uterus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

20 June 2018

Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

26 November 2018

Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752331

26 November 2018

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Applications of crude incidence curves

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Uterine sarcomas: the Curie Institut experience. Prognosis factors and adjuvant treatments

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of primary and adjuvant radiotherapy in the treatment of mixed Müllerian tumors of the corpus uteri

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison between different postoperative treatment modalities of uterine carcinosarcoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17822748

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2007.07.070

1 reference

Europe PubMed Central

19 August 2017

OpenCitations bibliographic resource ID

0 references

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30438454&oldid=1623131179"